Author: solispeptides

  • Tesamorelin: A Research Profile of the Stabilised GHRH Analogue

    Tesamorelin occupies a distinct place in the growth-hormone-secretagogue category, because unlike most of the research peptides discussed alongside it, it corresponds to a molecule that actually reached clinical approval for a specific medical indication. That history makes it one of the better-characterised peptides in the GHRH family, and a useful reference point for understanding how a growth-hormone-releasing-hormone analogue is engineered for stability. This profile explains what tesamorelin is, how it relates to the other GHRH-axis peptides, and what a research buyer should check when sourcing it.

    As with everything we publish, this concerns tesamorelin strictly as a research material. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing here is medical, dosing, or usage guidance.

    What is Tesamorelin?

    Tesamorelin is a synthetic peptide analogue of growth-hormone-releasing hormone (GHRH). Natural GHRH is a 44-amino-acid hormone produced in the hypothalamus that signals the pituitary to release growth hormone. Tesamorelin is built on the biologically active fragment of that hormone, with a chemical modification — a trans-3-hexenoic acid group attached to the N-terminus — that makes the molecule more stable and resistant to rapid breakdown than the unmodified sequence.

    That stabilising modification is the whole point of the molecule. Native GHRH and its shortest active fragments are fragile and short-lived; tesamorelin’s design keeps the GHRH-analogue structure intact for longer under experimental conditions. For the basics of how peptides like this are built, see our primer on what peptides are.

    Mechanism explored in the literature

    The mechanistic story of tesamorelin is that of a GHRH-receptor agonist:

    • GHRH-receptor agonism. Tesamorelin binds the GHRH receptor on the pituitary — the same receptor engaged by the body’s own GHRH — and in research models stimulates the release of growth hormone. Because it mimics the natural hormone rather than acting through a separate pathway, it is described as a GHRH analogue.
    • Engineered stability. The N-terminal modification is what differentiates tesamorelin mechanistically from unmodified GHRH fragments: it is designed to resist enzymatic degradation, giving a longer-lived interaction with the receptor system in study conditions.

    As always, this is a description of mechanisms studied in research, not a claim of outcomes. In a research context, tesamorelin is handled as a tool compound for probing the GHRH axis, not as an approved therapeutic for laboratory use.

    Tesamorelin vs Sermorelin vs CJC-1295

    The most useful way to understand tesamorelin is to place it next to the other GHRH-axis peptides, because all three are GHRH analogues that differ mainly in how they are stabilised:

    • Sermorelin corresponds to GHRH(1–29), the shortest fully active fragment. It is the closest to the “native” sequence and the shortest-acting of the three.
    • CJC-1295 takes that GHRH(1–29) backbone and adds modifications, and in the DAC version a mechanism for a much longer duration of action.
    • Tesamorelin takes the active GHRH fragment and stabilises it with its own N-terminal chemical group.

    The key concept is that these are variations on one theme — the GHRH receptor — engineered for different stability profiles, rather than three unrelated compounds. This is distinct from the ghrelin-receptor peptides such as Ipamorelin, which reach the same growth-hormone axis through a different receptor entirely, and are therefore often studied in combination with GHRH analogues rather than as substitutes for them.

    What’s on the market

    Across research-peptide suppliers, tesamorelin typically appears as:

    • Lyophilised powder in sealed vials, reconstituted in the laboratory, commonly in 5 mg and 10 mg sizes.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis. Because tesamorelin is a longer and more elaborate molecule than a short peptide, synthesis quality and documentation matter a great deal.

    Quality considerations when sourcing Tesamorelin

    For a research buyer, the documentation that separates credible tesamorelin from an unknown powder is the same rigorous set that applies to every peptide:

    • Mass spectrometry confirming the molecular identity of the analogue for the specific lot — important because the stabilising modification must actually be present and correct.
    • HPLC purity of ≥98%, shown as an actual chromatogram rather than a bare claim.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and current tesamorelin formats and pricing are in the catalogue.

    Frequently asked questions

    What is Tesamorelin?

    Tesamorelin is a synthetic, stabilised analogue of growth-hormone-releasing hormone (GHRH), based on the active fragment of GHRH with an N-terminal modification that makes it more resistant to breakdown. In research it is studied as a GHRH-receptor agonist.

    How is Tesamorelin different from Sermorelin?

    Both are GHRH analogues. Sermorelin corresponds to the short native GHRH(1–29) fragment, while tesamorelin adds a stabilising N-terminal modification to the active fragment for greater stability.

    Is Tesamorelin an approved drug?

    Tesamorelin corresponds to a molecule that has received approval for a specific human medical indication in some jurisdictions. However, the material Solis supplies is sold strictly as a research chemical for laboratory use only, and is not offered as a medicine or for human or veterinary use.

    In summary

    Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone, studied as a GHRH-receptor agonist and best understood as one of three related GHRH-axis peptides alongside Sermorelin and CJC-1295. As with any research peptide, what separates products is documentation: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Sermorelin (GRF 1-29): A Research Profile

    Sermorelin is, in a sense, the original of its family. Where peptides like CJC-1295 are engineered, stabilised variants, Sermorelin is the parent molecule they were built from — the shortest fragment of growth-hormone-releasing hormone that still does the job. This profile explains what Sermorelin is, how it works, how it relates to CJC-1295, and what to check when sourcing it.

    As with everything we publish, this concerns Sermorelin as a research material only. It is not an approved medicine for these purposes, and the peptides Solis supplies are for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is Sermorelin?

    Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone (GHRH) — often written GRF (1-29). Native GHRH is a 44-amino-acid hormone, but researchers established long ago that the first 29 residues are the biologically active fragment: the shortest portion that retains full GHRH activity. Sermorelin is that fragment.

    That makes it a GHRH analogue and a growth-hormone secretagogue — a compound studied for its ability to prompt the pituitary to release growth hormone. For the fundamentals of how peptides like this are built and characterised, see our primer on what peptides are.

    Mechanism explored in the literature

    Sermorelin’s mechanism is the cleanest in the GHRH family, precisely because it is the unmodified active fragment:

    • GHRH-receptor agonism. Sermorelin binds the GHRH receptor on the pituitary and, in research models, stimulates the release of growth hormone. It engages the same receptor and pathway as native GHRH.
    • Short-acting profile. Because it carries none of the stabilising substitutions or albumin-binding modifications found in engineered analogues, Sermorelin is comparatively short-acting in research systems — a pulsatile signal rather than a sustained one.

    As always, these are mechanisms studied in preclinical research models, not approved clinical outcomes for the uses discussed here.

    Sermorelin vs. CJC-1295

    This is the comparison worth understanding. CJC-1295 is essentially a modified, stabilised version of the same GRF (1-29) backbone: it adds amino-acid substitutions (and, in the DAC form, an albumin-binding complex) to resist enzymatic breakdown and extend duration. Sermorelin is the unmodified parent — same active region, no stabilising changes, shorter action.

    So the relationship is straightforward: Sermorelin is the original GRF (1-29); CJC-1295 is what you get when you engineer that fragment for longevity. Researchers choose between them depending on whether they want the native, short-acting signal or a longer-lasting one. Sermorelin is also frequently studied alongside ghrelin-receptor peptides such as Ipamorelin, which engage the growth-hormone axis through a complementary receptor.

    What’s on the market

    Across research-peptide suppliers, Sermorelin typically appears as:

    • Lyophilised powder in sealed vials, reconstituted in the laboratory, commonly in 2 mg and 5 mg sizes.
    • “Sermorelin” vs “GRF (1-29).” These names refer to the same molecule; a serious supplier’s documentation will make the sequence explicit.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis. Undocumented material is a different product regardless of the label.

    Quality considerations when sourcing Sermorelin

    For a research buyer, the documentation that separates credible Sermorelin from an unknown powder is the same rigorous set:

    • Mass spectrometry confirming the molecular identity of the peptide for the specific lot.
    • HPLC purity of ≥98%, shown as an actual chromatogram.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and current Sermorelin formats and pricing are in the catalogue.

    Frequently asked questions

    What is Sermorelin?

    Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone — GRF (1-29) — the shortest fully active GHRH fragment. In research it is studied as a growth-hormone secretagogue.

    Is Sermorelin the same as GRF (1-29)?

    Yes. “Sermorelin” and “GRF (1-29)” refer to the same molecule: the biologically active first 29 amino acids of GHRH.

    How is Sermorelin different from CJC-1295?

    CJC-1295 is a modified, stabilised version of the same GRF (1-29) backbone, engineered to last longer (the DAC form binds albumin for a much longer duration). Sermorelin is the unmodified parent fragment and is shorter-acting.

    Is Sermorelin an approved drug for these research uses?

    The material Solis supplies is a research chemical for laboratory use only, not for human or veterinary use, and is not sold as a medicine.

    In summary

    Sermorelin is GRF (1-29) — the shortest fully active fragment of growth-hormone-releasing hormone, and the unmodified parent of engineered analogues like CJC-1295. Its mechanism is clean GHRH-receptor agonism with a short, pulsatile profile, and it is frequently studied alongside ghrelin-receptor peptides such as Ipamorelin. It is a research material, not a therapeutic, and what separates products is documentation: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • GHK-Cu: A Research Profile of the Copper-Binding Peptide

    GHK-Cu is one of the most distinctive peptides in the research catalogue — you can often recognise it by sight, because its copper complex gives it a characteristic blue tint. It is also unusual in being a naturally occurring human peptide with a long history in the scientific literature. This profile explains what GHK-Cu is, the mechanisms studied around it, and what to check when sourcing it.

    As with everything we publish, this concerns GHK-Cu as a research material only. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use, and not a cosmetic. Nothing here is medical, dosing, or usage guidance.

    What is GHK-Cu?

    GHK-Cu is a copper-binding tripeptide — three amino acids (glycyl-L-histidyl-L-lysine, “GHK”) bound to a copper(II) ion. The GHK sequence occurs naturally in human plasma, where it has a well-documented ability to bind and carry copper. Its concentration in the body is reported in the literature to decline with age, which is part of why it has been so widely studied.

    This makes GHK-Cu a textbook example of a carrier peptide — a peptide whose function is intimately tied to the metal ion it transports. The copper is not incidental; it is central to the molecule’s chemistry and to the research interest around it. For the broader distinction between carrier peptides and other classes, see our primer on what peptides are.

    Mechanisms explored in the literature

    The GHK-Cu research literature is unusually deep for such a small molecule, and it clusters around a few themes:

    • Copper transport. As a copper-binding peptide, GHK-Cu is studied for how it delivers copper — a cofactor for many enzymes — into cellular systems in research models.
    • Skin and tissue-remodelling research. A large body of work examines GHK-Cu in the context of skin, collagen, and extracellular-matrix research, which is why it appears so often in cosmetic-science literature. In a research setting this is about matrix and remodelling pathways, not a cosmetic claim.
    • Gene-expression modulation. Some of the most-cited GHK-Cu papers report effects on the expression of large numbers of genes in cell models, positioning it as a tool for studying broad regulatory responses.
    • Antioxidant and angiogenic pathways. As with several repair-associated peptides, vascular and antioxidant pathways feature in the literature.

    The unifying thread is copper delivery and tissue-remodelling research. That combination — a specific carrier chemistry plus a wide-ranging regulatory footprint — is what has kept GHK-Cu in the literature for decades.

    What’s on the market

    Across research-peptide suppliers, GHK-Cu typically appears as:

    • Lyophilised powder with the characteristic blue colour of the copper complex, in sealed vials, commonly in 10 mg and larger (e.g. 50 mg) sizes.
    • GHK-Cu vs plain GHK. Some catalogues list the copper-complexed form (GHK-Cu) and the copper-free peptide (GHK) separately. They are chemically distinct; the copper is the defining feature of GHK-Cu.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis. Undocumented material is a different product regardless of the label.

    Quality considerations when sourcing GHK-Cu

    Because the copper complex defines the molecule, documentation should confirm both the peptide and its complexation:

    • Mass spectrometry confirming the molecular identity of the tripeptide for the specific lot.
    • HPLC purity of ≥98%, shown as an actual chromatogram.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and current GHK-Cu formats and pricing are in the catalogue.

    Frequently asked questions

    What is GHK-Cu?

    GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to a copper ion). In research it is studied as a carrier peptide for copper transport and in skin, collagen, and tissue-remodelling models.

    Why is GHK-Cu blue?

    The blue tint comes from the copper(II) ion bound to the GHK peptide. That copper complexation is the defining chemical feature of GHK-Cu, distinguishing it from the copper-free GHK peptide.

    Is GHK-Cu a cosmetic?

    No. Although GHK-Cu appears widely in cosmetic-science literature, the material Solis supplies is a research chemical for laboratory use only — not a cosmetic, medicine, or supplement, and not for human or veterinary use.

    What purity should research-grade GHK-Cu be?

    Research-grade material is typically characterised at ≥98% HPLC purity, with mass-spectrometry identity confirmation and a batch Certificate of Analysis.

    In summary

    GHK-Cu is a naturally occurring copper-binding tripeptide — a classic carrier peptide whose chemistry and research interest both centre on the copper ion it transports. Its literature spans copper delivery, skin and tissue-remodelling research, and broad gene-expression effects, making it one of the most-studied small peptides available. It is not a cosmetic or therapeutic; it is a research material. As always, what separates products is documentation: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • What ≥98% HPLC Purity Really Means

    Every research-peptide listing quotes a purity figure — almost always ≥98% HPLC. It has become the headline number of the industry, printed on vials and repeated in catalogues. But surprisingly few buyers can say precisely what it measures, what it leaves out, and why the number on its own is not enough. This article explains what HPLC purity actually tells you about a research peptide, and — just as importantly — what it does not.

    Everything here concerns peptides as research materials. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing below is medical, dosing, or usage guidance.

    What HPLC actually does

    HPLC stands for High-Performance Liquid Chromatography. It is an analytical technique that separates the different molecules in a sample so they can be measured individually. In the most common method for peptides — reverse-phase HPLC — the sample is pushed through a column, and different components travel through it at different speeds depending on their chemistry. As each component exits the column, a detector (usually measuring UV absorbance) records it as a peak.

    The result is a chromatogram: a graph of peaks over time. The target peptide shows up as one dominant peak; impurities and synthesis by-products show up as smaller peaks elsewhere. The size of each peak — specifically the area under it — reflects how much of that component is present.

    What “≥98% purity” means

    When a supplier states ≥98% HPLC purity, they mean this: of the total peak area detected in the chromatogram, at least 98% corresponds to the target peptide, and no more than 2% is everything else — truncated sequences, deletion products, and other related impurities left over from synthesis.

    In other words, it is a measure of how much of what’s detected is the molecule you want, expressed as a percentage of detector signal. A higher number means a cleaner synthesis and fewer related impurities. For research work, ≥98% is the widely accepted benchmark for research-grade material, because reproducible experiments depend on knowing your reagent is predominantly the intended compound. (For the basics of peptides and how they’re made, see our primer on what peptides are.)

    What ≥98% purity does not tell you

    This is where many buyers are misled — not by a false number, but by assuming the number says more than it does. HPLC purity is one measurement, and it is silent on several things that matter just as much:

    • It doesn’t confirm identity. Purity tells you the sample is 98% one main component — but not that the component is the correct peptide. Confirming the molecule is actually, say, BPC-157 and not something else of similar purity requires mass spectrometry, which measures molecular weight and identity. Purity and identity are two different questions.
    • It doesn’t tell you net peptide content. A “5 mg” vial contains 5 mg of material, but that mass includes water, counter-ions (salts), and residual solvents. The actual mass of peptide can be meaningfully lower. Net peptide content is a separate measurement from HPLC purity — a 99%-pure peptide can still be only 80% peptide by mass. (We’ll cover this distinction in a dedicated article.)
    • It doesn’t measure everything. Standard UV-based HPLC won’t flag things that don’t absorb at the detection wavelength, and it isn’t a test for endotoxins, sterility, or heavy metals. Those are separate analyses.

    None of this makes the ≥98% figure meaningless — it is genuinely important. It just means the number is one leg of a three-legged stool: purity, identity, and content.

    Why you should see the chromatogram, not just the number

    Here is the practical takeaway. Anyone can type “≥98%” on a label. What’s much harder to fake is the actual chromatogram — the graph showing one clean, dominant peak with minimal noise around it. A credible supplier provides the real HPLC trace for the specific batch, not just a claimed percentage.

    When you can see the chromatogram, you can judge it yourself: Is there one sharp main peak, or a cluster of near-peaks suggesting related impurities? Is the baseline clean? A number is a claim; a chromatogram is evidence. As we put it on our Quality & Analytics page, purity you can check beats purity you’re told.

    What to ask a supplier for

    For any research peptide, the documentation set that actually establishes quality is:

    • The HPLC report — showing ≥98% purity and the chromatogram for that lot.
    • Mass spectrometry — confirming the molecular identity of the peptide.
    • A batch Certificate of Analysis (CoA) — tying purity, identity, and (ideally) net peptide content to the specific vial you’re buying.

    Together those answer the three real questions: Is it pure? Is it the right molecule? How much peptide is actually in there?

    Frequently asked questions

    What does ≥98% HPLC purity mean?

    It means that in the HPLC analysis, at least 98% of the total detected peak area corresponds to the target peptide, with impurities and synthesis by-products making up 2% or less. It’s a measure of how much of the detected material is the intended compound.

    Does HPLC purity confirm the peptide’s identity?

    No. Purity measures how much of one main component is present, not what that component is. Confirming identity requires mass spectrometry, which measures molecular weight. Purity and identity are separate checks.

    Is ≥98% purity the same as net peptide content?

    No. Purity is a percentage of detector signal; net peptide content is the actual mass of peptide in the vial after accounting for water, salts, and solvents. A highly pure peptide can still have a lower net peptide content by weight.

    Why should I ask for the chromatogram?

    Because a purity percentage is just a claim, while the chromatogram is the underlying evidence. Seeing one clean, dominant peak for the specific batch lets you verify the number rather than take it on trust.

    In summary

    “≥98% HPLC purity” means at least 98% of the material detected in the chromatogram is the target peptide — a genuine and important measure of a clean synthesis. But it is not a measure of identity (that’s mass spectrometry) or of net peptide content (a separate mass measurement), and it isn’t a test for everything. Treat purity, identity, and content as three distinct questions, insist on seeing the actual chromatogram rather than just the number, and look for a lot-specific Certificate of Analysis that ties it all together. See how Solis documents this on the Quality & Analytics page, or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Ipamorelin: A Research Profile of the Selective Growth-Hormone-Releasing Peptide

    Ipamorelin is one of the most studied peptides in the growth-hormone-secretagogue category, and it is best known for a single defining trait: selectivity. Among the research peptides that engage the growth-hormone axis, ipamorelin is the one most often described in the literature as acting cleanly on its target. This profile explains what ipamorelin is, how it works, why it is so frequently paired with CJC-1295, and what to check when sourcing it.

    As with everything we publish, this concerns ipamorelin as a research material only. It is not an approved medicine, and the peptides Solis supplies are for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is Ipamorelin?

    Ipamorelin is a synthetic pentapeptide — a chain of five amino acids — classified as a growth-hormone-releasing peptide (GHRP). In functional terms it is a ghrelin-receptor agonist: it binds the growth-hormone secretagogue receptor (GHS-R1a), the same receptor engaged by the natural hormone ghrelin.

    That places ipamorelin in the broader family of growth-hormone secretagogues — compounds studied for their interaction with the growth-hormone axis. What distinguishes it within that family is its reputation in the research literature for being selective: engaging the growth-hormone pathway with comparatively little reported effect on other hormones such as cortisol and prolactin, which some earlier-generation GHRPs influenced more. For the fundamentals of how peptides like this are built and characterised, see our primer on what peptides are.

    Mechanism explored in the literature

    The mechanistic story of ipamorelin is centred on the ghrelin / GHS-R1a receptor:

    • Ghrelin-receptor agonism. Ipamorelin binds GHS-R1a and, in research models, stimulates the release of growth hormone from the pituitary. This is the same receptor system the body uses via ghrelin, which is why ipamorelin is described as a ghrelin mimetic.
    • Reported selectivity. A recurring theme in the literature is that ipamorelin’s action appears comparatively targeted to the growth-hormone pathway. This selectivity is the main reason it became a reference compound in GHRP research.

    It is worth restating the framing: these are mechanisms studied in preclinical research models, not approved clinical outcomes. Ipamorelin is not an approved therapeutic.

    Why Ipamorelin and CJC-1295 are studied together

    Ipamorelin is very frequently discussed alongside CJC-1295, and there is a clear mechanistic reason. The two peptides engage the growth-hormone axis through different, complementary receptor pathways:

    • CJC-1295 is a GHRH analogue — it acts on the GHRH receptor.
    • Ipamorelin is a ghrelin mimetic — it acts on the GHS-R1a (ghrelin) receptor.

    Because they work through two separate routes into the same axis, they are commonly studied as a pair in the research literature, and catalogues routinely list them together. Understanding that they are mechanistically distinct — not two versions of the same thing — is the key concept for anyone evaluating the GH-secretagogue category.

    What’s on the market

    Across research-peptide suppliers, ipamorelin typically appears as:

    • Lyophilised powder in sealed vials, reconstituted in the laboratory, commonly in 5 mg and 10 mg sizes.
    • Standalone or paired listings. Because of the CJC-1295 pairing, some suppliers list ipamorelin both on its own and as part of a research “blend.” As always, the meaningful information is in the documentation, not the marketing.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis. Undocumented material is a different product regardless of the label.

    Quality considerations when sourcing Ipamorelin

    For a research buyer, the documentation that separates credible ipamorelin from an unknown powder is the same rigorous set:

    • Mass spectrometry confirming the molecular identity of the pentapeptide for the specific lot.
    • HPLC purity of ≥98%, shown as an actual chromatogram rather than a bare claim.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and current ipamorelin formats and pricing are in the catalogue.

    Frequently asked questions

    What is Ipamorelin?

    Ipamorelin is a synthetic pentapeptide and a selective growth-hormone-releasing peptide (GHRP) that acts as a ghrelin-receptor (GHS-R1a) agonist. In research it is studied as a growth-hormone secretagogue.

    Why is Ipamorelin described as “selective”?

    Because in the research literature it appears to engage the growth-hormone pathway with comparatively little reported effect on other hormones such as cortisol and prolactin, relative to some earlier GHRPs. That relative selectivity is its defining characteristic.

    Why is Ipamorelin paired with CJC-1295?

    Because the two act on different, complementary receptors within the growth-hormone axis — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor — so they are frequently studied together as a pair.

    Is Ipamorelin an approved drug?

    No. Ipamorelin is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only and is not intended for human or veterinary use.

    In summary

    Ipamorelin is a selective growth-hormone-releasing peptide — a five-amino-acid ghrelin-receptor agonist studied for its comparatively targeted action on the growth-hormone axis. Its defining trait is selectivity, and its most common research context is pairing with the GHRH analogue CJC-1295, which engages the same axis through a different receptor. It is not an approved therapeutic, and, as with any research peptide, what separates products is documentation: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • CJC-1295 Explained: DAC vs No-DAC (Mod GRF 1-29)

    CJC-1295 is one of the most frequently studied peptides in the growth-hormone-axis research literature, and it comes in two forms that are constantly confused: with DAC and without DAC. Choosing between them — and knowing which one is actually in the vial — is the single most important thing to understand about this peptide. This profile explains what CJC-1295 is, what the DAC modification does, and how the two versions differ.

    As with everything we publish, this concerns CJC-1295 as a research material only. It is not an approved medicine, and the peptides Solis supplies are for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is CJC-1295?

    CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Its backbone corresponds to a modified fragment of GHRH — the first 29 amino acids, the functionally active region — with a small number of amino-acid substitutions that improve stability against enzymatic breakdown compared with native GHRH.

    Because GHRH is the body’s signal to the pituitary to release growth hormone, CJC-1295 is studied in the research literature as a growth-hormone secretagogue — a compound investigated for its interaction with the GHRH receptor and its role in growth-hormone-axis research models. For the broader family it belongs to, see our overview of growth-hormone secretagogues and our primer on what peptides are.

    The DAC modification: the key distinction

    “DAC” stands for Drug Affinity Complex. It is an added chemical group that allows the peptide to bind reversibly to albumin, the most abundant protein in blood plasma. This binding is the entire point of the two-version split:

    • CJC-1295 with DAC. The albumin-binding complex dramatically extends how long the molecule persists in a research system — from minutes to a matter of days in the literature. This long-acting property is why “CJC-1295 DAC” is studied as a sustained GHRH-receptor research tool.
    • CJC-1295 without DAC. The same stabilised GHRH(1-29) backbone, but without the albumin-binding group, so it acts over a much shorter window. This short-acting form is frequently referred to in the market as “Mod GRF (1-29)” — the two names describe the same no-DAC molecule.

    So the DAC-vs-no-DAC choice is fundamentally a choice about duration of action in the research model: long and sustained, versus short and pulsatile. Neither is “better” in the abstract — they are different tools suited to different experimental questions.

    Mechanism explored in the literature

    Both versions share the same core mechanism: agonism at the GHRH receptor on the pituitary, studied for its role in stimulating the release of growth hormone in research models. The difference lies entirely in the pharmacokinetics — how long that signal is sustained — not in the receptor being engaged.

    CJC-1295 is also commonly studied alongside ghrelin-receptor peptides such as ipamorelin, because the two engage the growth-hormone axis through different, complementary receptor pathways. This pairing appears frequently across the research literature and in supplier catalogues.

    What’s on the market

    • Two clearly separate products. A serious supplier lists CJC-1295 DAC and CJC-1295 no-DAC as distinct items, because they are distinct molecules with very different behaviour. If a listing is vague about which one it is, that is a red flag.
    • Lyophilised powder in sealed vials, reconstituted in the laboratory, commonly in 2 mg and 5 mg sizes.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis. Undocumented material is a different product regardless of the label.

    Quality considerations when sourcing CJC-1295

    Because two similar-sounding versions exist, documentation is what tells them apart:

    • Mass spectrometry confirming which molecule — DAC or no-DAC — is actually present in the lot.
    • HPLC purity of ≥98%, shown as a real chromatogram.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and both CJC-1295 versions and their pricing are in the catalogue.

    Frequently asked questions

    What is the difference between CJC-1295 with and without DAC?

    The DAC (Drug Affinity Complex) group lets the peptide bind albumin, greatly extending how long it persists in a research system — days rather than minutes. CJC-1295 with DAC is long-acting; CJC-1295 without DAC (also called Mod GRF 1-29) is short-acting. Both share the same GHRH-receptor mechanism.

    Is CJC-1295 no-DAC the same as Mod GRF (1-29)?

    Yes — “CJC-1295 no-DAC” and “Mod GRF (1-29)” are two names commonly used for the same short-acting, stabilised GHRH(1-29) molecule without the albumin-binding complex.

    Is CJC-1295 an approved drug?

    No. CJC-1295 is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only and is not intended for human or veterinary use.

    What purity should research-grade CJC-1295 be?

    Research-grade material is typically characterised at ≥98% HPLC purity, with mass-spectrometry identity confirmation and a batch Certificate of Analysis.

    In summary

    CJC-1295 is a stabilised GHRH(1-29) analogue studied as a growth-hormone secretagogue, and it exists in two forms distinguished entirely by the DAC albumin-binding modification: a long-acting version (with DAC) and a short-acting version (without DAC, also called Mod GRF 1-29). Both share the same GHRH-receptor mechanism; they differ in duration. Because the two are easily confused, mass-spec identity, ≥98% HPLC purity, and a lot-specific CoA are what confirm which one you are actually buying. See the Quality & Analytics page, browse the catalogue, or read the companion Ipamorelin profile.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Peptide Legality in the EU: REACH, RUO & Where Solis Operates

    “Are research peptides legal in the EU?” is one of the most common questions buyers ask, and it is also one of the most misunderstood. The short answer is that research peptides occupy a specific, legitimate lane in EU regulation — the research-chemical lane — provided they are sold, labelled, and handled correctly. This article explains how that lane works, where the important legal lines sit, and how Solis Peptides operates within it from the Czech Republic.

    This is general educational information about the regulatory landscape, not legal advice. Everything Solis supplies is sold strictly for laboratory research use only — not for human or veterinary use — and end users remain responsible for compliance with the laws of their own country.

    The key distinction: research chemicals vs. medicines

    The single most important concept in this whole topic is the line between a research chemical and a medicinal product. Under EU law, a “medicinal product” is broadly something presented as treating or preventing disease, or administered to humans to restore, correct, or modify a physiological function. Medicinal products require marketing authorisation through the European Medicines Agency or national authorities — a long, expensive approval process.

    Research peptides sold on a Research Use Only (RUO) basis are not medicinal products. They are not presented for treating anyone, they carry no health or dosing claims, and they are sold as reagents for laboratory experimentation. That is precisely why responsible suppliers are so disciplined about language: the moment a peptide is marketed with therapeutic claims or dosing instructions, it risks being reclassified as an unapproved medicine — which is a completely different, heavily regulated category.

    Where REACH fits in

    Chemicals in the EU are governed primarily by REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals). REACH is the framework under which substances are registered and their safe handling documented. Research and development activity has specific provisions within REACH, and substances used in scientific R&D are treated differently from bulk commercial chemicals placed on the consumer market.

    For a research-peptide distributor, operating in the REACH chemical lane means treating the products as what they are — laboratory chemicals supplied to researchers and businesses — with appropriate documentation, rather than as consumer goods or health products. This is the regulatory home in which RUO peptides legitimately sit.

    The lines that matter

    Several separate bodies of law define the edges of the research-peptide lane. Understanding them is what keeps a supplier and its customers on the right side:

    • Medicines law. No marketing authorisation means the product cannot be sold or promoted for human or veterinary treatment. RUO labelling and the absence of therapeutic claims keep the product out of this category.
    • Food & supplement law. Research peptides are not foods, food supplements, or novel foods, and must not be presented as ingestible products. They are laboratory reagents.
    • Cosmetics law. They are likewise not cosmetics and are not sold for application to the body.
    • Anti-doping (sport). A number of peptides studied in the growth-hormone and repair literature appear on the World Anti-Doping Agency prohibited list. This is relevant context for the research community but is a matter of sporting rules, separate from whether a substance may be supplied as a research chemical.

    The common thread is that presentation and intended use determine the legal category. The same molecule can be a lawfully supplied research reagent or an unlawful unapproved medicine depending entirely on how it is sold and labelled — which is why the RUO framing is not a marketing slogan but a compliance boundary.

    Where Solis operates

    Solis Peptides operates from the Czech Republic as an EU-based research-peptide manufacturer and distributor. That means:

    • EU establishment and fulfilment. Being established in the EU (Czechia) and fulfilling within the single market simplifies movement of goods between member states compared with importing from outside the EU.
    • Strict RUO positioning. Every product is sold for laboratory research use only, with no health, dosing, or benefit claims, and documentation framed around what has been studied in the literature.
    • Business and research customers. The model is built around supplying researchers, laboratories, and businesses — including wholesale and white-label — rather than positioning peptides as consumer health products.

    You can read more about the company’s positioning on the About Solis Peptides page, and about documentation standards on the Quality & Analytics page.

    The buyer’s responsibility

    One point deserves emphasis: EU-level framing does not override national law, and it does not remove the end user’s responsibilities. Individual member states can and do have their own rules, and the person or organisation purchasing a research chemical is responsible for ensuring their intended use is lawful where they are. A reputable supplier sells on a clear RUO basis; the buyer confirms they are using the material appropriately, in a genuine research context, in compliance with local regulations.

    Frequently asked questions

    Are research peptides legal to buy in the EU?

    Research peptides sold on a Research Use Only basis occupy the research-chemical lane and are generally supplied lawfully to researchers and businesses within the EU, provided they are not marketed or used as medicines, supplements, or cosmetics. National rules vary and end-user compliance is the buyer’s responsibility. This is general information, not legal advice.

    Why do suppliers insist on “Research Use Only”?

    Because it is the compliance boundary between a research chemical and an unapproved medicine. Selling peptides with therapeutic or dosing claims risks reclassifying them as medicinal products, which require marketing authorisation. RUO labelling keeps the product in the correct regulatory category.

    Does being EU-based make a difference?

    Yes, practically. An EU-established supplier fulfilling within the single market avoids the customs and import complexity of shipping research chemicals from outside the EU, and operates under the EU’s harmonised chemical framework.

    In summary

    Research peptides are lawful within the EU’s research-chemical lane when they are sold and labelled correctly — as Research Use Only laboratory reagents, without medical, dosing, or benefit claims. The boundaries are set by medicines, food, cosmetics, and (for sport) anti-doping rules, and the deciding factor is always presentation and intended use. Solis operates from Czechia on a strict RUO basis with EU fulfilment, and buyers remain responsible for lawful use in their own jurisdiction. Learn more on our Quality & Analytics and About pages, or start with our primer on what peptides are.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, legal, or usage advice.

  • TB-500: A Research Profile of the Thymosin β4 Fragment

    TB-500 is one of the most frequently studied research peptides in the tissue-repair and cell-migration literature, and it is almost always mentioned in the same breath as its flagship counterpart, BPC-157. It is also one of the most commonly mislabelled peptides on the market, because of a subtle but important relationship to a naturally occurring protein called thymosin beta-4. This profile explains what TB-500 is, how it relates to thymosin β4, the mechanisms explored in the research literature, and what to check when sourcing it.

    As with everything we publish, this concerns TB-500 as a research material only. It is not an approved medicine, and the peptides Solis supplies are for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is TB-500?

    TB-500 is a synthetic peptide associated with the actin-binding region of thymosin beta-4 (Tβ4). Thymosin β4 is a naturally occurring 43-amino-acid protein that plays a central role in regulating actin, one of the fundamental structural proteins inside cells. TB-500 is the laboratory designation most often used for synthetic material corresponding to the functionally active portion of that molecule.

    This is where the naming gets important. In the research-peptide market, “TB-500” and “thymosin beta-4” are frequently used interchangeably, but they are not strictly the same thing: full-length Tβ4 is the complete 43-residue protein, while TB-500 commonly refers to a shorter synthetic fragment centred on the key actin-binding motif. When sourcing, the label alone does not tell you which molecule is in the vial — the Certificate of Analysis and mass-spectrometry data do. For the general distinction between peptides and full proteins, see our primer on what peptides are.

    Why TB-500 is studied

    The research interest in TB-500 flows directly from the biology of thymosin β4, which sits at the centre of actin regulation, cell migration, and angiogenesis research. Because actin dynamics underpin how cells move, divide, and reorganise during repair, a peptide that engages this system is a valuable tool for probing those processes in preclinical models.

    In the published animal and in-vitro literature, TB-500 and thymosin β4 have been examined in models involving cell migration, vascular response, and connective-tissue research. As with BPC-157, it is essential to frame this accurately: this is preclinical, mechanism-oriented research, not approved clinical use, and TB-500 is not an approved therapeutic.

    Mechanisms explored in the literature

    The mechanistic story of TB-500 is unusually clean, because it traces back to one well-characterised function of thymosin β4:

    • Actin sequestration. Thymosin β4 is one of the principal G-actin-sequestering peptides in cells — it binds monomeric actin and helps regulate the pool available for building the actin filaments that drive cell shape and movement. The actin-binding motif (often written LKKTETQ) is the functional heart of the molecule.
    • Cell migration. Because actin dynamics govern how cells move, the literature has examined thymosin β4 and TB-500 in the context of cell-migration research — relevant to how tissue reorganises during repair.
    • Angiogenesis. As with a number of repair-associated peptides, vascular and angiogenic pathways feature in the research literature.

    The key concept is actin regulation. That single mechanism is what ties together the migration, vascular, and repair angles that appear across the TB-500 literature.

    TB-500 and BPC-157: why they’re studied together

    TB-500 is frequently discussed alongside BPC-157 because the two are the flagship peptides of the tissue-repair research category — but they are mechanistically distinct. BPC-157’s literature centres on the VEGFR2 and nitric-oxide pathways; TB-500’s centres on actin regulation and cell migration. They are different tools that happen to be studied in overlapping research contexts, which is why catalogues and literature reviews so often pair them.

    What’s on the market

    • Lyophilised powder. The standard research format — freeze-dried peptide in a sealed vial, reconstituted in the laboratory, commonly in 5 mg and 10 mg sizes.
    • “TB-500” vs “Thymosin β4” labelling. These terms are used loosely across the market. A serious supplier’s documentation will make clear exactly which molecule and sequence the lot corresponds to.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis. Anything undocumented is a different product regardless of the name on the label.

    Quality considerations when sourcing TB-500

    Given the naming ambiguity, documentation matters even more for TB-500 than for a typical peptide. When sourcing it, look for:

    • Mass spectrometry confirming the molecular identity of the specific lot — this resolves the TB-500-versus-Tβ4 question definitively.
    • HPLC purity of ≥98%, shown as an actual chromatogram.
    • A lot-specific Certificate of Analysis (CoA) linking those results to your vial, and clarity on net peptide content.

    We document all of this for our material on the Quality & Analytics page, and current TB-500 formats and pricing are in the catalogue.

    Frequently asked questions

    What is TB-500?

    TB-500 is a synthetic peptide associated with the actin-binding region of thymosin beta-4, a naturally occurring protein central to actin regulation. In research it is used as a tool compound to study cell migration, angiogenesis, and tissue-repair pathways.

    Is TB-500 the same as thymosin beta-4?

    Not exactly. Thymosin β4 is the full 43-amino-acid protein; TB-500 commonly refers to a shorter synthetic fragment centred on the key actin-binding motif. The two terms are often used interchangeably in the market, so mass-spectrometry data is what confirms which molecule is actually present.

    Is TB-500 an approved drug?

    No. TB-500 is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only and is not intended for human or veterinary use.

    What purity should research-grade TB-500 be?

    Research-grade material is typically characterised at ≥98% HPLC purity, with mass-spectrometry identity confirmation and a batch Certificate of Analysis.

    In summary

    TB-500 is a synthetic peptide tied to the actin-binding region of thymosin beta-4, and its research profile is built around one well-characterised mechanism: actin regulation, and the cell-migration and angiogenesis research that follows from it. It is frequently paired with BPC-157 as a flagship tissue-repair research peptide, though the two work through different pathways. Because “TB-500” and “thymosin β4” are used loosely across the market, documentation — especially mass-spec identity alongside ≥98% HPLC purity and a lot-specific CoA — is what tells you what you are actually buying. See our Quality & Analytics page, browse the catalogue, or read the companion BPC-157 profile.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • BPC-157: A Research Profile of the Pentadecapeptide

    Few research peptides have generated as much discussion in recent years as BPC-157. It appears constantly in preclinical literature, in laboratory supplier catalogues, and in conversations about tissue-repair research models. For anyone evaluating it as a research material, though, the signal can be hard to separate from the noise. This profile lays out what BPC-157 actually is, the mechanisms explored in the published literature, and what a buyer should understand about the forms on the market.

    Everything below concerns BPC-157 strictly as a research material. It is not an approved medicine anywhere, and the peptides Solis supplies are sold for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is BPC-157?

    BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids. The name “BPC” stands for Body Protection Compound, and the “157” is a laboratory designation. Its sequence corresponds to a partial fragment associated with a protein originally identified in gastric juice, which is why the research literature often frames it in the context of the gastrointestinal environment.

    As a fifteen-residue peptide it is small, well-defined, and straightforward to synthesise by solid-phase peptide synthesis, then purify and characterise. One reason it attracts research interest is a reputation in the literature for relative stability compared with many larger, more fragile peptides — a practical property when a molecule needs to survive experimental conditions long enough to be studied. For the basics of how peptides are built and characterised, see our primer on what peptides are.

    Why BPC-157 is studied

    The research attention around BPC-157 centres on angiogenesis and tissue-repair pathways in preclinical models. In the published animal and in-vitro literature, it has been used as a tool compound to probe how repair and vascular-signalling systems behave under various conditions. Researchers have examined it in models involving connective tissue, the gastrointestinal tract, and vascular response, among others.

    It is important to read this literature for what it is: preclinical, mechanism-focused research, largely in animal and cell models, rather than approved clinical use in humans. BPC-157 has not been approved as a therapeutic by the major regulators, and describing it accurately means talking about what has been studied — not asserting outcomes for people.

    Mechanisms explored in the literature

    Several mechanistic threads recur across the BPC-157 research literature. A responsible summary presents them as areas of investigation, not settled facts:

    • The VEGF / VEGFR2 pathway. A significant body of work has examined BPC-157 in relation to vascular endothelial growth factor signalling and the VEGFR2 receptor, a central pathway in the formation of new blood vessels (angiogenesis).
    • The nitric oxide (NO) system. Multiple studies have investigated interactions with the nitric-oxide pathway, which is involved in vascular tone and a wide range of signalling processes.
    • Growth-factor and cytoskeletal signalling. Research models have looked at pathways such as FAK–paxillin signalling and various growth-factor cascades relevant to how cells migrate and organise during repair.

    The through-line is vascular and repair signalling. What makes BPC-157 useful as a research tool is precisely that it can be introduced into a model system to interrogate these pathways in a controlled way.

    What’s on the market

    If you compare research-peptide catalogues, you will find BPC-157 offered in a few different forms, and the differences matter when sourcing:

    • Lyophilised powder. The standard research format — a freeze-dried peptide in a sealed vial, reconstituted in the laboratory. Most research-grade BPC-157 is sold this way, commonly in 5 mg and 10 mg vial sizes.
    • “Stable” / arginine-salt variants. Some suppliers list a stabilised salt form. As always, the meaningful question is not the marketing name but the accompanying analytics.
    • Purity grades. This is where products genuinely diverge. Research-grade material should be characterised at ≥98% HPLC purity, with a batch Certificate of Analysis. Lower-grade or undocumented material is a different product regardless of the label.

    Because BPC-157 is popular, it is also widely counterfeited and under-documented in the grey market. The single most useful habit when sourcing it is to look past the name on the vial to the paperwork behind it.

    Quality considerations when sourcing BPC-157

    For a research buyer, three documents separate a credible BPC-157 from an unknown powder:

    • HPLC purity report confirming ≥98% and showing the actual chromatogram, not just a number.
    • Mass spectrometry confirming the molecular identity of the pentadecapeptide for the specific lot.
    • A batch Certificate of Analysis (CoA) tying those results to the vial you are buying.

    Net peptide content matters too: a “5 mg” vial refers to a mass that includes counter-ions and residual solvent, so actual peptide content can vary between suppliers. We cover how we document all of this on our Quality & Analytics page, and you can see current BPC-157 formats and pricing in our catalogue.

    Frequently asked questions

    What is BPC-157?

    BPC-157 is a synthetic pentadecapeptide — a fifteen-amino-acid chain whose sequence corresponds to a partial fragment associated with a protein identified in gastric juice. In research it is used as a tool compound to study angiogenesis and tissue-repair pathways.

    Is BPC-157 an approved drug?

    No. BPC-157 is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only, and is not intended for human or veterinary use.

    What purity should research-grade BPC-157 be?

    Research-grade material is typically characterised at ≥98% HPLC purity, supported by mass-spectrometry identity confirmation and a batch Certificate of Analysis.

    Why is documentation so important for BPC-157?

    Because BPC-157 is widely sold and widely counterfeited, the label alone tells you little. An HPLC trace, an MS identity confirmation, and a lot-specific CoA are how a buyer verifies that the vial contains what it claims to.

    In summary

    BPC-157 is a small, stable, well-studied synthetic pentadecapeptide that has become a common tool in preclinical angiogenesis and tissue-repair research, with mechanistic literature centred on the VEGFR2 and nitric-oxide pathways. It is not an approved therapeutic, and it is sold strictly as a research material. When sourcing it, the differences between products come down to documentation: verified ≥98% HPLC purity, mass-spec identity, and a lot-specific Certificate of Analysis. See how Solis documents its material on the Quality & Analytics page, browse formats in the catalogue, or read the companion profile on TB-500.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • What Are Peptides? A Clear, Practical Guide for Research

    Peptides sit at the centre of a huge amount of modern life-science research — and yet, for anyone coming to the field for the first time, the word itself can be confusing. Are peptides the same as proteins? Are they drugs? Supplements? Chemicals? The honest answer is that a peptide is a very specific kind of molecule, and once you understand what it is and how it behaves, the rest of the landscape becomes much easier to navigate.

    This guide explains what peptides are, how they differ from proteins, how they are made, and how they work at a molecular level. It is written for people evaluating research peptides — laboratory researchers, procurement teams, and distributors — rather than for any personal or clinical purpose. Everything here relates to peptides as research materials. The peptides Solis supplies are sold strictly for laboratory research use only, not for human or veterinary use, and nothing in this article is medical, dosing, or usage guidance.

    What is a peptide?

    A peptide is a short chain of amino acids linked together in a defined sequence. Amino acids are the small organic building blocks that living systems use to assemble almost everything functional inside a cell. There are twenty standard amino acids, and the specific order in which they are strung together determines what the resulting molecule is and how it behaves.

    The link between one amino acid and the next is called a peptide bond — a chemical bond formed when the carboxyl group of one amino acid joins the amino group of the next, releasing a molecule of water. Chain enough amino acids together through these bonds and you have a peptide. Two amino acids make a dipeptide, three a tripeptide, and a longer run a polypeptide.

    Because the sequence is so precise, even a single amino acid substitution can change a peptide’s shape, stability, and behaviour. This is exactly why sequence fidelity and purity matter so much when peptides are used as research reagents: the molecule you think you are studying and the molecule actually in the vial need to be the same thing.

    Peptides vs. proteins: where is the line?

    Peptides and proteins are made from the same raw materials — amino acids joined by peptide bonds — so where does one end and the other begin? The distinction is mostly about size and structure. By convention, a chain of roughly 50 amino acids or fewer is called a peptide, while longer chains that fold into stable three-dimensional shapes are called proteins. The cut-off is a convention rather than a hard law of chemistry, which is why borderline molecules get described either way. Insulin, for instance, has 51 amino acids and is often called a small protein.

    The more useful difference is functional. Proteins typically fold into elaborate, stable structures that let them act as enzymes, scaffolds, or molecular machines. Peptides are generally smaller and more flexible, and many work as signalling molecules — short messages that fit a specific receptor and tell a cell to do something.

    How peptides are made

    There are two broad routes by which peptides come into existence: the body makes them, or a laboratory synthesises them.

    In living systems (endogenous peptides). Cells build peptides using the same machinery that builds proteins, translating genetic information into precise sequences, then cutting and modifying the results. Many well-known molecules are peptides in this sense — oxytocin, vasopressin, glucagon, and a range of hormone-releasing and hormone-inhibiting factors.

    In the laboratory (synthetic peptides). Research peptides are manufactured chemically, most often by solid-phase peptide synthesis (SPPS), in which the peptide is built one amino acid at a time on a solid resin support, each residue added, coupled, and deprotected in a tightly controlled cycle. Once assembled, the peptide is cleaved from the resin and purified.

    The purification and verification steps are where quality is won or lost. Crude synthetic peptide always contains some truncated or side-product molecules, so it is purified — typically by reverse-phase high-performance liquid chromatography (RP-HPLC) — and its identity confirmed by mass spectrometry. A credible research peptide is characterised by a stated HPLC purity (commonly ≥98% for research-grade material) and a batch Certificate of Analysis (CoA). You can read how we handle this on our Quality & Analytics page.

    How peptides work at a molecular level

    Because peptides come in so many sequences, they do not all work the same way. But most peptides that attract research attention fall into a few functional patterns.

    Signalling peptides. The largest and most studied category. A signalling peptide has a shape that fits a specific receptor — often on the surface of a cell. When it binds, it triggers a cascade inside the cell, like a key turning a lock. Peptide hormones work this way: the peptide is the message, the receptor is the mailbox, and the cell’s internal machinery acts on the message.

    Carrier peptides. Some peptides bind and transport other molecules. A frequently cited example is the copper-binding tripeptide GHK-Cu, studied precisely because it carries a copper ion.

    Enzyme-modulating peptides. Others act on enzymes — inhibiting or influencing their activity — which makes them valuable tools for probing biochemical pathways in a controlled way.

    Across all of these, a recurring theme is specificity. Peptides tend to interact with defined targets rather than acting broadly, which is exactly what makes them attractive research tools.

    The main categories of research peptides

    If you browse a research-peptide catalogue, the entries usually cluster into a few families:

    • Growth-hormone secretagogues and releasing factors — peptides studied around the growth-hormone axis, including GHRH analogues and ghrelin-receptor research peptides (e.g. sermorelin, tesamorelin, CJC-1295, ipamorelin).
    • Regenerative and repair-research peptides — investigated in tissue and cellular research contexts (e.g. BPC-157, TB-500).
    • Copper and cosmetic-research peptides — carrier peptides such as GHK-Cu.
    • Neuropeptides and cognition-research peptides — examined in neurological and behavioural research models (e.g. Semax, Selank).
    • Longevity and metabolic-research peptides — sequences studied in ageing and metabolic pathways (e.g. Epitalon, MOTS-c).

    Each has its own literature, mechanisms of interest, and market. We publish a dedicated profile for each peptide we carry — see the full range in our catalogue.

    Why peptides matter in research

    Peptides occupy a valuable middle ground: large and specific enough to interact with precise biological targets, but small and well-defined enough to be synthesised chemically, purified to a known standard, and characterised exactly. That combination is unusual, and it is why peptides have become such important tools across biochemistry, cell biology, pharmacology research, and materials science.

    Three properties stand out. Peptides are modular — change one amino acid and study the effect. They are specific — a given sequence tends to engage a defined target. And they are reproducible when made well — a properly synthesised, purified, and documented peptide can be the same from batch to batch, which is the foundation of any experiment others are expected to repeat. A research peptide is only as useful as its documentation: two vials with the same label but different real purities are, for research purposes, two different materials.

    What “Research Use Only” actually means

    You will see the phrase Research Use Only (RUO) on legitimate research-peptide products, including everything Solis supplies. It is not marketing boilerplate — it defines what the material is sold for and how it may lawfully be handled.

    Research Use Only means the product is intended for laboratory research and experimental purposes only. It is not a medicine, supplement, or cosmetic, and not intended for human or veterinary use. It has not been evaluated or approved as a therapeutic product, and it should be handled only by, or under the supervision of, qualified individuals in an appropriate research environment, in line with all applicable local regulations. The RUO framing is also what keeps the product in the correct regulatory lane — the research-chemical lane — which is why responsible vendors describe mechanisms studied in the literature rather than making health, benefit, or dosing claims. Read more on our About Solis Peptides page.

    Frequently asked questions

    Is a peptide the same as a protein?

    Not quite. Both are chains of amino acids joined by peptide bonds, but peptides are shorter — by convention around 50 amino acids or fewer — and generally more flexible, while proteins are longer chains that fold into stable three-dimensional structures.

    How are research peptides made?

    Most are produced by solid-phase peptide synthesis, in which the sequence is assembled one amino acid at a time on a solid support, then purified (usually by reverse-phase HPLC) and confirmed by mass spectrometry.

    What does ≥98% HPLC purity mean?

    It means that when the material is analysed by high-performance liquid chromatography, at least 98% of the detected content corresponds to the target peptide, with impurities making up the remainder. Research-grade material is typically characterised at this level, with a batch Certificate of Analysis to document it.

    What does “Research Use Only” mean?

    It means the product is intended solely for laboratory research and is not for human or veterinary use, not a medicine, supplement, or cosmetic, and has not been approved as a therapeutic. It should be handled only in an appropriate research setting by qualified people.

    In summary

    A peptide is a short, precisely sequenced chain of amino acids linked by peptide bonds — smaller than a protein, often flexible, and frequently acting as a specific biological signal. Research peptides are synthesised chemically, purified to a documented standard, and characterised by sequence, purity, and Certificate of Analysis. Handled correctly and sold on the correct Research Use Only basis, they are among the most versatile and reproducible tools available to modern life-science research. If you are evaluating research peptides, the two things worth checking first are always the same: the purity and the paperwork behind it. See how Solis documents both on our Quality & Analytics page, or browse the full range in our catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.